The FDA Has Accepted Bristol Myers Squibb's Supplemental Biologics License Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) As Potential First-line Treatment For Adult Patients With Unresectable Hepatocellular Carcinoma, With Prescription Drug User Fee Act Goal Date Of April 21, 2025
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Bristol Myers Squibb's application for Opdivo and Yervoy as a potential first-line treatment for unresectable hepatocellular carcinoma, with a decision expected by April 21, 2025.
August 21, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's application for Opdivo and Yervoy as a first-line treatment for liver cancer has been accepted by the FDA, with a decision due by April 2025.
The acceptance of the application by the FDA is a positive regulatory step for Bristol Myers Squibb, indicating potential future revenue from these drugs if approved. This news is likely to have a positive short-term impact on BMY's stock price as it reflects progress in their drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100